$1.14/ day, billed weekly
Cancel anytime

(Ads Free, Unlimited access)

NO CREDIT CARD REQUIRED

VBI Vaccines Inc. (VBIVQ)VBIVQ

VBI Vaccines Inc.

$0.02

Delayed price

PASS

BUY Advisory
Profitable SELL
Loss-Inducing SELL

Profit
Loss
PASS (Skip invest)*

Time period over

ALL
YEAR
MONTH
WEEK

Time period over

Upturn Advisory Summary

09/30/2024: VBIVQ (1-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Performance

Type: Stock	Upturn Star Rating	Today’s Advisory: PASS
Historic Profit: -68.36%	Upturn Advisory Performance 1	Avg. Invested days: 15
Profits based on simulation	Stock Returns Performance 1	Last Close 09/30/2024

Type: Stock	Today’s Advisory: PASS
Historic Profit: -68.36%	Avg. Invested days: 15
Upturn Star Rating	Stock Returns Performance 1
Profits based on simulation Last Close 09/30/2024	Upturn Advisory Performance 1

Key Highlights

Company Size ETF	Market Capitalization 0 USD
Price to earnings Ratio -	1Y Target Price -
Dividends yield (FY) -	Basic EPS (TTM) -
Volume (30-day avg) 195683	Beta -
52 Weeks Range 0.00 - 0.98	Updated Date 08/15/2024

Company Size ETF	Market Capitalization 0 USD	Price to earnings Ratio -	1Y Target Price -
Dividends yield (FY) -	Basic EPS (TTM) -	Volume (30-day avg) 195683	Beta -
52 Weeks Range 0.00 - 0.98	Updated Date 08/15/2024

Earnings Date

Report Date 2024-11-12	When BeforeMarket
Estimate -	Actual -

Report Date 2024-11-12

When BeforeMarket

Estimate -

Actual -

Profitability

Profit Margin -

Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -

Return on Equity (TTM) -

Valuation

Trailing PE -	Forward PE -
Enterprise Value -	Price to Sales(TTM) -
Enterprise Value to Revenue -	Enterprise Value to EBITDA -
Shares Outstanding -	Shares Floating -
Percent Insiders -	Percent Institutions -

Trailing PE -	Forward PE -	Enterprise Value -	Price to Sales(TTM) -
Enterprise Value to Revenue -	Enterprise Value to EBITDA -	Shares Outstanding -	Shares Floating -
Percent Insiders -	Percent Institutions -

Analyst Ratings

Rating -	Target Price -	Buy -
Strong Buy -	Hold -	Sell -
Strong Sell -

Rating -	Target Price -	Buy -	Strong Buy -
Hold -	Sell -	Strong Sell -

About VBI Vaccines Inc.

Exchange	NASDAQ	Headquaters	Cambridge, MA, United States
IPO Launch date	-	President, CEO & Director	Mr. Jeffery R. Baxter FCMA
Sector	Healthcare	Website	https://www.vbivaccines.com
Industry	Biotechnology	Full time employees	131
Headquaters	Cambridge, MA, United States
President, CEO & Director	Mr. Jeffery R. Baxter FCMA
Website	https://www.vbivaccines.com
Website	https://www.vbivaccines.com
Full time employees	131

VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers hepatitis B (HBV) vaccine under the PreHevbrio, PreHevbri, and Sci-B-Vac brand names. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma cancer vaccine immunotherapeutic candidate; VBI-1501, a prophylactic cytomegalovirus vaccine candidate; and VBI-2501 to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited, the National Research Council of Canada, and Coalition for Epidemic Preparedness Innovations. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.

https://www.upturn.io

Disclosure Privacy Policy Terms of Use Sitemap Contact Us

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.